Kerala Supplies Generic Risdiplam to Children with SMA
Kerala began providing Natco’s generic risdiplam, marketed as Natsmart, to children with spinal muscular atrophy (SMA) through its free-medicine programme in October 2026. It replaced Roche’s branded medicine, Evrysdi, which the state had supplied since 2022.
Price and labelling concerns
Natco’s generic risdiplam was reported to cost around ₹8,000–₹15,900 per bottle, compared with approximately ₹5.2 lakh–₹6.5 lakh for Roche’s medicine. Concerns arose after some bottles distributed to children carried the label “Physician Sample/Clinical Trials Only”. Hospital authorities and the government clarified that these were samples supplied under the rate contract, not for clinical trials, and said the generic drug had regulatory approval. Health Minister K. Muralidharan defended continued provision of the medicine and assured that it was safe for use.
Important Facts for Exams
- SMN2 splicing: Risdiplam modifies SMN2 messenger RNA splicing to include exon 7, increasing the concentration of functional survival motor neuron protein.
- Oral treatment: Risdiplam was the first oral medication approved by the US FDA to treat spinal muscular atrophy.
- SMA genetic modifier: Most 5q SMA arises from biallelic pathogenic SMN1 variants; the number of SMN2 copies often modifies disease severity.